Astellas Pharma Inc (YPH MU) stock market data APIs
€13.0033
0(0%)
as of March 16, 2026
Try our APIs with
free plan!
Astellas Pharma Inc Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for YPH.MU.
Prev. Close
13.0033
Open
13.0033
High
13.0033
Low
13.0033
52 wk Range
7.6751-14.01
Market Cap
25 701 M
Dividends (Yield)
1.4099
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Astellas Pharma Inc data using free add-ons & libraries
Get Astellas Pharma Inc Fundamental Data
Astellas Pharma Inc Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Astellas Pharma Inc News
New
Will Linzess Continue to Aid IRWD's Top Line in 2026 After a Soft Q4?
Ironwood Pharmaceuticals’ IRWD sole marketed product, Linzess (linaclotide), is approved for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults and pediatric patients aged...
Pfizer Bladder Cancer Trial Results Deepen Oncology Growth And Risk Debate
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Pfizer (NYSE:PFE) and Astel...
Pfizer Inc. (PFE) and Astellas Report Positive Phase 3 EV-304 Results for PADCEV Plus Keytruda in Bladder Cancer
Pfizer Inc. (NYSE:PFE) is among the 13 Most Undervalued S&P 500 Stocks to Invest In.Pfizer Inc. (PFE) and Astellas Report Positive Phase 3 EV-304 Results for PADCEV Plus Keytruda in Bladder Cancer On...
Pfizer Inc. (PFE) and Astellas Pharma Announce Positive Results From the Phase 3 EV-304 Clinical Trial for PADCEVTM
Pfizer Inc. (NYSE:PFE) is one of the best cheap stocks under $50 to buy right now. Pfizer Inc. (NYSE:PFE) and Astellas Pharma Inc. announced on February 27 positive results from the Phase 3 EV-304 cli...
Get Astellas Pharma Inc fresh news feed via Financial News API
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
